Making Medicine

The Making Medicine Podcast, where science, policy, and innovation meet.

[Charles Crain @CCrainNAM]

Great to join @johnbstanford on the @MakingMedPod to talk about how to drive American innovation and make healthcare more affordable for manufacturers and their workers. 

📻Tune in to hear how PBM reform, 340B transparency, and continued regulatory certainty from the FDA will keep the workforce at full strength while lowering the cost of healthcare.
https://t.co/RV4pl5nJFW

[Making Medicine @MakingMedPod]

Many Americans are discovering that paying cash for medicine can sometimes cost less than using insurance. 💊

John Stanford joined the Brian Kilmeade show to discuss Trump RX, healthcare affordability, PBMs, and why patients continue to face barriers accessing prescribed medicines.

Follow us for critical biotech and healthcare policy coverage
🎙️ Full interview at the link in bio

#Healthcare #DrugPricing
@johnbstanford @kilmeade @FoxNews @foxnewsradio @incub8coalition @US_FDA @HHSGov @NIH @WhiteHouse @MedicineMa80739

[Making Medicine @MakingMedPod]

We should be aggressively courting brainpower from around the world.
Scientific talent may become one of the defining factors in biotech competitiveness over the next decade 🧠

Follow us for critical biotech and healthcare policy coverage
🎙️ Full episode at the link in bio

@johnbstanford @incub8coalition @RepScottPeters @US_FDA @HHSGov @WhiteHouse @realDonaldTrump

#biotech #innovation

[Making Medicine @MakingMedPod]

The “pill penalty” debate wasn’t just about drug pricing, it was about future biotech investment and innovation incentives. 💊
Will policies tied to Medicare negotiation change what types of medicines companies pursue?

Follow us for critical biotech and healthcare policy coverage
🎙️ Full episode at the link in bio

@johnbstanford @incub8coalition @RepScottPeters @US_FDA @HHSGov

#biotech #drugpricing #congress

[Making Medicine @MakingMedPod]

They’ve read our playbook and they’re doing a pretty good job.
China’s biotech growth is becoming one of the biggest strategic conversations in healthcare and innovation policy 🧬🇨🇳
Follow us for critical biotech and healthcare policy coverage
🎙️ Full episode at the link in bio

@johnbstanford @incub8coalition @RepScottPeters @US_FDA @HHSGov

#biotech #china

[Making Medicine @MakingMedPod]

@johnbstanford says it twice because it's true: High deductibles mean "insured" patients are effectively paying cash anyway. Coverage alone isn't enough anymore.

Watch the full episode of the @MakingMedPod at the link in our bio

[Making Medicine @MakingMedPod]

@johnbstanford warns: Only 9% of experts would start a biotech career in Europe. We are importing the policies that caused their collapse. 🇺🇸⚠️
Watch the full episode of the @MakingMedPod at the link in our bio

[Making Medicine @MakingMedPod]

@johnbstanford breaks down why a @pfizer drug was 10x more expensive on TrumpRx than Mark Cuban's site. Is the new platform actually saving you money?

Watch the full episode of the @MakingMedPod at the link in our bio

[Making Medicine @MakingMedPod]

@jefakst of @biospace reveals to @johnbstanford why the @FDA is "not functioning." Reversals, rug pulls, and the Moderna chaos are making the industry "uninvestable". 📉
Watch the full episode of the @MakingMedPod at the link in our bio

[Making Medicine @MakingMedPod]

In the newest @MakingMedPod, @johnbstanford sits down with @jefakst of @biospace to unpack FDA reversals, the Moderna mRNA flu vaccine decision, biotech investment risk, and Most Favored Nation drug pricing policy.
We break down regulatory uncertainty at the @FDA, vaccine investment challenges, Alzheimer’s drug development, and the rise of psychedelics in mental health treatment. We also discuss new polling showing Americans are more concerned with overall affordability, like groceries, housing, and health insurance, than with lowering prescription drug prices.
Watch the full episode on YouTube:
https://t.co/4BrztB5GPK

#FDA #Biotech #DrugPricing #Pharmaceuticals #HealthcarePolicy

[Making Medicine @MakingMedPod]

John Stanford explains why they want high prices: they keep half the profit. The math on your prescription doesn't add up, and it’s not an accident. It’s a business model. 📉 Watch the full episode at the link in our bio

[Making Medicine @MakingMedPod]

John Stanford explains why they want high prices: they keep half the profit. The math on your prescription doesn't add up, and it’s not an accident. It’s a business model. 📉 Watch the full episode at the link in our bio

[Making Medicine @MakingMedPod]

John Stanford reveals the FDA is skipping Congress to approve drugs in months, not years. Staff are revolting, claiming it breaks scientific norms. Is this necessary innovation or a safety disaster waiting to happen? ⚖️ Watch the full episode at the link in our bio.

[INCUBATE @incub8coalition]

In the newest @MakingMedPod, @johnbstanford breaks down the biggest biotech stories of 2025 -- from national security priorities and venture funding shifts to AI-driven drug development, FDA approvals, and PBM reform efforts. Full episode on YouTube: https://t.co/2fLyutD38p

[Alliance of U.S. Startups and Inventors for Jobs @USIJorg]

Last month, @SenThomTillis joined @JohnBStanford for @MakingMedPod -- warning that foreign free-riding harms American life sciences.

Give the episode a listen: https://t.co/WAJ6yuFzZj

[Making Medicine @MakingMedPod]

🎙️ NEW: Making Medicine ft. @SenThomTillis

A deep dive into the IP foundations of American innovation — and how policy choices like MFN-style price controls could reshape the future of U.S. R&D.

📜 Patent eligibility reform — and why uncertainty is already stalling breakthrough science
🔐 How strong IP protections keep America ahead in the global biotech race
🌐 MFN-style price controls + the risk of importing foreign pricing models
⚖️ Regulatory clarity that investors need to back new cures
💡 What it will take to preserve U.S. leadership in life sciences

Watch the full conversation → https://t.co/teRFVZbZLJ

[INCUBATE @incub8coalition]

🎙️ NEW: Making Medicine ft. @SenThomTillis

This episode breaks down the policies shaping America’s innovation edge — with a spotlight on MFN-style price controls and what they could mean for U.S. R&D.

🇨🇳 China’s accelerating biotech competition
📜 Patent eligibility + its “dampening effect on innovation”
🌐 MFN and why foreign price benchmarks threaten future cures
⚖️ Regulatory certainty + investment
💡 How the U.S. stays ahead

Watch the full convo → https://t.co/I7gEUpy7QJ

🎧 Follow @MakingMedPod for more biotech + policy insights.